Compare AARD & ZH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AARD | ZH |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.1M | 293.3M |
| IPO Year | N/A | N/A |
| Metric | AARD | ZH |
|---|---|---|
| Price | $12.28 | $3.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $31.11 | N/A |
| AVG Volume (30 Days) | 148.5K | ★ 300.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $20.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.88 | $3.23 |
| 52 Week High | $19.58 | $6.32 |
| Indicator | AARD | ZH |
|---|---|---|
| Relative Strength Index (RSI) | 43.27 | 43.61 |
| Support Level | $11.14 | $3.41 |
| Resistance Level | $13.58 | $3.76 |
| Average True Range (ATR) | 1.05 | 0.18 |
| MACD | -0.14 | -0.02 |
| Stochastic Oscillator | 31.45 | 17.65 |
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.